<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dienogest (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dienogest (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Dienogest (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="17069" href="/d/html/17069.html" rel="external">see "Dienogest (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52871178"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ASPEN-Dienogest;</li>
<li>JAMP Dienogest;</li>
<li>Visanne</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F13450887"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiandrogen; Progestin</li></ul></div>
<div class="block doa drugH1Div" id="F13451029"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="46c9c161-3a00-43b9-b6a4-9d35ba3a22b8">Endometriosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;">
<b>Endometriosis:</b>
<b>Oral:</b> 2 mg once daily. Dosing may begin on any day of the menstrual cycle.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990985"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doha drugH1Div" id="F50988125"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment: No dosage adjustment provided in manufacturer's labeling (has not been studied); dienogest undergoes hepatic metabolism and therefore systemic exposure may be increased.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: Use is contraindicated in patients with a history of or current severe hepatic disease.</p></div>
<div class="block dop drugH1Div" id="F46279105"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="46c9c161-3a00-43b9-b6a4-9d35ba3a22b8">Endometriosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endometriosis:</b> Children ≥12 years and Adolescents: Females (postmenarche): Oral: 2 mg once daily; has been studied for up to 12 months of therapy.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51117833"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block dohp drugH1Div" id="F51117834"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment: There are no dosage adjustments provided in manufacturer's labeling; dienogest undergoes hepatic metabolism and therefore systemic exposure may be increased.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: Use is contraindicated in patients with a history of or current severe hepatic disease.</p></div>
<div class="block adr drugH1Div" id="F13450934"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults and adolescents.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Endocrine &amp; metabolic: Change in menstrual flow (including amenorrhea, frequent bleeding, infrequent bleeding, irregular bleeding, prolonged bleeding)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris (2%), alopecia (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Loss of libido (2%), spotting (≤1%), weight gain (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (2%), nausea (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Breast engorgement (≤5%), mastalgia (≤5%), ovarian cyst (3%), uterine hemorrhage (≤1%), vaginal hemorrhage (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (2%), depressed mood (3%), headache (7%), irritability (1%), migraine (1%), nervousness (1%), sleep disorder (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema, palpitations</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermatitis, onychoclasis, pruritus, skin photosensitivity, skin pigmentation, xeroderma</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hot flash</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress, constipation, diarrhea, flatulence, gastrointestinal inflammation, increased appetite, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Breast induration, fibrocystic breast disease, genital discharge, lump in breast, pelvic pain, urinary tract infection, vaginal dryness, vulvar dryness, vulvovaginal candidiasis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety, depression, disturbance in attention, dysautonomia, emotional lability, feeling of heaviness (extremities), mood changes</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain, limb pain, muscle spasm, ostealgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Dry eye syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Anovulation</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Decreased bone mineral density (adolescents: loss or plateauing)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Nervous system: Insomnia (Lee 2021), major depressive disorder (including suicidal ideation) (Lee 2021)</p></div>
<div class="block coi drugH1Div" id="F13450892"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to dienogest or any component of the formulation; undiagnosed abnormal vaginal bleeding; active venous thromboembolic disorder; history of or current arterial and cardiovascular disease (eg, myocardial infarction, ischemic heart disease, cerebrovascular accident); diabetes mellitus with vascular involvement; history of or current severe hepatic disease where liver function tests remain abnormal; history of or current hepatic neoplasia (benign or malignant); known or suspected sex-hormone-dependent malignancy; ocular lesions due to ophthalmic vascular disease, such as partial or complete vision loss or defect in visual fields; current or history of migraine with focal aura; breastfeeding; known or suspected pregnancy.</p></div>
<div class="block war drugH1Div" id="F13450893"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding: Use is associated with irregular menstrual bleeding (eg, amenorrhea, infrequent or frequent bleeding, prolonged bleeding) and may be aggravated in some patients (eg, those with fibroids). Bleeding patterns generally show a reduced intensity over time. If bleeding irregularities continue with prolonged use, appropriate diagnostic measures should be taken to rule out endometrial pathology (eg, endometrial sampling, pelvic ultrasound). Consider discontinuation of therapy with prolonged heavy bleeding. Pretreatment menstrual bleeding patterns return within 2 months of therapy discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bone mineral density loss: Dienogest has been associated with plateauing and loss of bone mineral density (BMD) which may not be completely reversible; BMD loss may be greater with prolonged use of dienogest and the effects may be of greater concern during adolescence and periods of bone accretion. It is not known if use of dienogest during adolescence will decrease peak bone mass and increase the risk of osteoporosis. A mean decrease in BMD in the lumbar spine of 1.2% has been observed in patients 12 to &lt;18 years of age after 12 months of therapy; BMD increased towards pretreatment levels within 6 months of therapy discontinuation. Risks/benefits of therapy in adolescents should be evaluated prior to initiating therapy and regularly during therapy. BMD monitoring should be considered in adolescents as clinically appropriate. In a small study of adult patients, a reduction in mean BMD was not observed 6 months after initiating therapy though long-term data are not available. Risk assessment should also be performed in patients of any age at increased risk of osteoporosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Chloasma: May occur occasionally; patients with a history of chloasma should avoid sun or ultraviolet radiation exposure during therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cholestatic jaundice: Patients with a prior history of cholestatic jaundice during pregnancy or due to the use of sex steroids should discontinue use of dienogest if cholestatic jaundice reoccurs during therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic tumors: Rare cases of benign and malignant hepatic tumors have been reported with use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ovarian cysts: Persistent ovarian cysts which are often asymptomatic may occur during therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pruritus: Patients with a prior history of pruritus during pregnancy or due to use of sex steroids should discontinue dienogest therapy if pruritus reoccurs during therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thromboembolic disorders: Use with caution in patients with risk factors for venous thromboembolism (VTE), including personal or family history of VTE, obesity, prolonged immobilization, major surgery, or major trauma. Discontinue use if an arterial or venous thrombotic event occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Breast cancer: In patients at risk for breast cancer due to family history or susceptibility genes (<i>BRCA1</i>,<i> BRCA2</i>), it is unclear if combination hormonal contraceptives increase the risk for breast cancer and there are insufficient data specific to progestin-only contraceptives. However, breast cancer is a hormonal-sensitive tumor and the prognosis for patients with a current or recent history of breast cancer may be worse with hormonal contraceptive use (CDC [Curtis 2016]; SGO/ASRM [Chen 2019]). Although this formulation of dienogest is not used as a contraceptive, warnings associated with progestin-only therapies are applicable.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with risk factors for cardiovascular disease (eg, hypertension, older age, smoking). The risk of stroke may be increased in patients with hypertension. Discontinue if clinically significant hypertension develops during therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Depression: Use with caution in patients with depression; discontinue use with onset of clinically relevant depression or with aggravation of pre-existing depression.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: May impair glucose tolerance; use caution in patients with diabetes or a history of gestational diabetes mellitus.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Smoking: The risk of cardiovascular side effects and the risk of BMD decline is increased in patients who smoke cigarettes. Patients should be advised not to smoke.</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgical patients: Whenever possible, use should be discontinued at least 4 weeks prior to and through 2 weeks following major surgery or other surgeries known to have an increased risk of thromboembolism or during periods of prolonged immobilization.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not intended for use as a contraceptive. However, warnings associated with progestin-only therapies are applicable</p></div>
<div class="block prod-avail drugH1Div" id="F13451041"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Not available in the US</p></div>
<div class="block geq drugH1Div" id="F53040752"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block dinfoc drugH1Div" id="F52871179"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Visanne: 2 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg</p></div>
<div class="block adm drugH1Div" id="F13451035"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer preferably at the same time each day with liquid and without regard to meals. Tablets should be taken continuously regardless of any vaginal bleeding. If vomiting and/or diarrhea occur within 3 to 4 hours of administration, repeat dose.</p></div>
<div class="block admp drugH1Div" id="F52620922"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer preferably at the same time each day with liquid and without regard to meals. Tablets should be taken continuously regardless of any vaginal bleeding. If vomiting and/or diarrhea occur within 3 to 4 hours of administration, repeat dose.</p></div>
<div class="block use drugH1Div" id="F13450888"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Not approved in the US</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Endometriosis:</b> Management of pelvic pain associated with endometriosis</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Not for use prior to menarche or post menopause.</p></div>
<div class="block mst drugH1Div" id="F13450884"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Visanne may be confused with Vyvanse</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">ALERT: Canadian Boxed Warning: Health Canada-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299188"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F10327802"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Progestins may enhance the adverse/toxic effect of Chlorprothixene. Progestins may enhance the therapeutic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Dienogest.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Dienogest.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Dienogest.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Dienogest.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Progestins may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking progestins.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ulipristal: May diminish the therapeutic effect of Progestins. Progestins may diminish the therapeutic effect of Ulipristal.<i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49297846"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Pregnancy status should be evaluated prior to use. Nonhormonal contraception (eg, barrier method) should be used if contraception is needed; use of hormonal contraceptives is not recommended during dienogest therapy. Ovulation is often inhibited during therapy; however, this product is not intended for use as a contraceptive. Normal menstruation usually returns within 2 months of therapy discontinuation.</p></div>
<div class="block pri drugH1Div" id="F13450889"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Use is contraindicated during pregnancy. Based on limited data, inadvertent exposure in pregnancy has not shown adverse effects to the fetus.</p></div>
<div class="block brc drugH1Div" id="F13450891"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if dienogest is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Use is contraindicated in breastfeeding patients. The risk of thromboembolism may be increased immediately postpartum.</p></div>
<div class="block dic drugH1Div" id="F56594734"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;">Ensure adequate calcium and vitamin D intake.</p></div>
<div class="block mop drugH1Div" id="F13451039"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Evaluate pregnancy status prior to initiating therapy; adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding; bone mineral density (prior to therapy in patients at risk for osteoporosis and as clinically indicated in adolescents); BP; depression; endometrial-related pain.</p></div>
<div class="block pha drugH1Div" id="F13450980"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Dienogest is a steroid with antiandrogen properties that lacks androgen, mineralocorticoid or glucocorticoid activity. Exhibits strong progestogenic effects although it binds uterine progesterone receptors with an affinity much lower (about one-tenth) than that of progesterone. Decreases estradiol production and thus suppresses estradiol's trophic effects on eutopic and ectopic endometrium. Inhibits cellular proliferation via direct antiproliferative, immunologic, and antiangiogenic effects.</p></div>
<div class="block phk drugH1Div" id="F13451013"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid and almost complete</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 40 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~90% nonspecifically to albumin</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP3A4 to inactive metabolites</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~91%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~9 to 10 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: ~1.5 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (primarily as inactive metabolites)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F12992817"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Visanne</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Desire | Visanne</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Aridya | Endovelle | Metrissa | Visanne | Zafrilla</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Dinasane | Visanne</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Daizy | Dinogest | Endosis | Metrinor | Neogest</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Dimetrum | Pauline | Visannette | Zafrilla</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Visanne | Zafrilla</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Alandre | Allurene | Alurax | Dienogeste | Dine | Dinora | Diost | Intime | Kalist | Ludili ed | Meluren | Pietra ed</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Dienogest mepha | Dienogest mylan | Dienogest Sandoz | Dienogest spirig hc | Metrissa | Visanne | Visannette</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Alondra | Dalgiet | Disven | Pietra ed</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Ablalondra | Alondra | Desire | Dienomet | Metrinelle | Pietra ed | Visanne</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Aridya | Endovelle | Nometrum | Tubanis | Zafrilla</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Diemono | Dienogest aristo | Dienogest glenmark | Dinuve | Dyonelle | Endovelle | Verybel | Visannette | Zafrilla</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Desire | Edysven | Visanne</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Abl alondra | Dalgiet | Minosta | Visanne</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Endodrava | Visanne</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Dienogest aristo | Dimetrio | Endovelle | Visannette | Zafril</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Visanne</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Dienogest besins | Dienogest stragen | Endovelle</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Dimetrum | Endovela | Sawis | Visanne</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Dimetrum | Zalkya</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Visannette</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Visanne</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Visanne</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Dienogest alvogen | Tubanis | Zafrilla</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Endovelle | Nelandoz | Visanne</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Zafrilla</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Cipgest | Deinest | Dienocare | Dienofem | Dienofic | Dinobliss | Dinogest | Dinopil | Dinotas | Dinotop | Dinowise | Dng | Duramp | Dynocad | Encede | Endobreak | Endobye | Endoheal | Endonok | Endoreg | Endosis | Mirumigest | Uvazest | Visanne</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Devicius | Dienogest aristo | Dienogest Sandoz | Endodien | Endovelle | Visanne | Zafrilla</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Visanne</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Dienogest f | Dienogest kissei | Dienogest mochida | Dienogest sawai | Dienogest towa</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Visanne</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Dieno | Diesanne | Losanne | U&amp; | Visanne | You n</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Visanne</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Dienosis | Visanne</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Sawis</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Dimetrum | Pauline | Visannette</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Endogest | Visanne</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Nuntera | Visannette</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Visanne</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Visanne</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Dalgiet | Edual | Visanne</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Visanne</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Aridya | Diemono | Endofemine | Endovelle | Probella | Symdieno | Visanne | Zafrilla</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Endovelle | Metrius | Zafril</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Desire | Fiorigyn | Pietra | Visanne</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Visanne</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Visanne | Zafrilla</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Alvovizan | Visanne | Zafrilla</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Visanne</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Dienogest besins | Dienosis | Endovelle | Visanne</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Dienosis</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Endovelle</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Visanne</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Vezia | Visanne</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Dienomet</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Visanne</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Diemono | Dienogest alvogen | Dimetrio | Endometrion | Marita | Mitren | Sawis</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Desire | Dienomax | Visanne</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Dienogest adco | Dienogest pharmc | Visafem | Visanne</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Visanne</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-31606136">
<a name="31606136"></a>Chen LM, Blank SV, Burton E, Glass K, Penick E, Woodard T. Reproductive and hormonal considerations in women at increased risk for hereditary gynecologic cancers: Society of Gynecologic Oncology and American Society for Reproductive Medicine Evidence-Based Review. <i>Fertil Steril</i>. 2019;112(6):1034-1042. doi:10.1016/j.fertnstert.2019.07.1349<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dienogest-united-states-not-available-drug-information/abstract-text/31606136/pubmed" id="31606136" target="_blank">31606136</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27467196">
<a name="27467196"></a>Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. medical eligibility criteria for contraceptive use, 2016. <i>MMWR Recomm Rep</i>. 2016;65(3):1-103. doi:10.15585/mmwr.rr6503a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dienogest-united-states-not-available-drug-information/abstract-text/27467196/pubmed" id="27467196" target="_blank">27467196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34622869">
<a name="34622869"></a>Lee SM, Park JK. Dienogest-induced major depressive disorder with suicidal ideation: a case report. <i>Medicine (Baltimore)</i>. 2021;100(40):e27456. doi:10.1097/MD.0000000000027456<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dienogest-united-states-not-available-drug-information/abstract-text/34622869/pubmed" id="34622869" target="_blank">34622869</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20444534">
<a name="20444534"></a>Strowitzki T, Faustmann T, Gerlinger C, Seitz C. Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study. <i>Eur J Obstet Gynecol Reprod Biol</i>. 2010;151(2):193-198. doi:10.1016/j.ejogrb.2010.04.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dienogest-united-states-not-available-drug-information/abstract-text/20444534/pubmed" id="20444534" target="_blank">20444534</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20089522">
<a name="20089522"></a>Strowitzki T, Marr J, Gerlinger C, Faustmann T, Seitz C. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. <i>Hum Reprod</i>. 2010;25(3):633-641. doi:10.1093/humrep/dep469<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dienogest-united-states-not-available-drug-information/abstract-text/20089522/pubmed" id="20089522" target="_blank">20089522</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Visanne (dienogest) [product monograph]. Mississauga, Ontario, Canada: Bayer Inc; February 2016.</div>
</li></ol></div><div id="topicVersionRevision">Topic 17068 Version 217.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
